Professional headshot of a person wearing a white medical coat over a light blue dress shirt and patterned burgundy tie. The portrait is framed from the chest up against a light gray background. The subject faces slightly to one side while looking toward the camera. Soft natural lighting and a neutral backdrop create a clean, professional appearance suitable for a healthcare or academic profile.

FACULTY

Brian Boulmay

Professor of Clinical Medicine

Medicine - Hematology and Oncology

Academic Office:

Louisiana Cancer Research Center
1700 Tulane Ave, Room 504
New Orleans, LA 70112

504-568-2348

 

Clinical Office:

University Medical Center
2000 Canal Street
New Orleans, LA 70112

504-702-5700

 

Bio

Brian Boulmay earned his medical degree from Louisiana State University. He went on to complete his internship and residency in Internal Medicine, as well as his fellowship in Hematology/Oncology, at the University of Florida. He is board certified in Internal Medicine, Hematology, and Medical Oncology. His interest is in head & neck, lung and other aerodigestive tumors. He sees patients at UMCNO and at the VA Medical Center in New Orleans. 

Affiliated Hospitals & Clinics

  • University Medical Center
  • New Orleans VA Medical Center

Publications

1. Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma. Nghiem P, Bhatia S, Lipson EJ, Sharfman WH, Kudchadkar RR, Brohl AS, Friedlander PA, Daud A, Kluger HM, Reddy SA, Boulmay BC, Riker A, Burgess MA, Hanks BA, Olencki T, Kendra K, Church C, Akaike T, Ramchurren N, Shinohara MM, Salim B, Taube JM, Jensen E, Kalabis M, Fling SP, Homet Moreno B, Sharon E, Cheever MA, Topalian SL. J Immunother Cancer. 2021 Apr;9(4):e002478. doi: 10.1136/jitc-2021-002478. PMID: 33879601

2. Durable Tumor Regression and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line Therapy. Nghiem P, Bhatia S, Lipson EJ, Sharfman WH, Kudchadkar RR, Brohl AS, Friedlander PA, Daud A, Kluger HM, Reddy SA, Boulmay BC, Riker AI, Burgess MA, Hanks BA, Olencki T, Margolin K, Lundgren LM, Soni A, Ramchurren N, Church C, Park SY, Shinohara MM, Salim B, Taube JM, Bird SR, Ibrahim N, Fling SP, Homet Moreno B, Sharon E, Cheever MA, Topalian SL. J Clin Oncol. 2019 Mar 20;37(9):693-702. doi: 10.1200/JCO.18.01896. Epub 2019 Feb 6. PMID: 30726175

3. Images in clinical medicine. Herpes labialis and facial-nerve paralysis. Park EP, Boulmay BC. N Engl J Med. 2014 Mar 13;370(11):1048. doi: 10.1056/NEJMicm1305786. PMID: 24620868

4. Hemoglobin SO-Arab and α-thalassemia diagnosed in an adult: A case-based review of the hemoglobinopathies. Zacharia G, Maronge GF, Brazda FW, Boulmay BC. Am J Med Sci. 2013 Oct;346(4):325-7. doi: 0.1097/MAJ.0b013e318275625b. PMID: 23221516 Review.

5. Forgotten histories. Boulmay BC. Oncologist. 2011;16(4):537-8. doi: 10.1634/theoncologist.2010-0351. Epub 2011 Mar 4. PMID: 21378079

6. Restoration of medical oncology services at LSU Interim Public Hospital in New Orleans after Hurricane Katrina: a two-year experience of LSUHSC. Harmon RE, Boulmay BC. J La State Med Soc. 2011 May-Jun;163(3):144-PMID: 21827061

7. Adjuvant high-dose interferon-{alpha} for resected melanoma in a patient with HIV infection. Saba NS, George TJ Jr, Boulmay BC. Oncologist. 2010;15(7):695-8. doi: 10.1634/theoncologist.2009-0335. Epub 2010 Jun 16. PMID: 20555019 Free PMC article.

8. Definitive altered fractionation radiotherapy and concomitant weekly cisplatin for locally advanced head and neck cancer. Boulmay BC, Chera BS, Morris CG, Kirwan J, Riggs CE, Lawson M, Mendenhall WM. J Clin Oncol. 2009 Oct;32(5):488-91. doi: 10.1097/COC.0b013e318194f418. PMID: 19528791